| All Releases |
 |
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
Nov 19, 2008
|
10.0 KB
|
| |
ISELIN, N.J., Nov 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Study did not achieve statistical significance
Pharmos Corporation (Nasdaq: PARS) today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine.
The multi-center, randomized...
|
|
 |
Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
Nov 13, 2008
|
9.1 KB
|
| |
Iselin, NJ, November 13, 2008 - Pharmos Corporation (Nasdaq: PARS) today announced that it received notice from The Nasdaq Stock Market ("Nasdaq") on November 11, 2008 that the Company is not in compliance with Nasdaq Marketplace Rule 4310©(3), which requires the Company to have a minimum of $2,500,000 in...
|
|
 |
Pharmos Corporation Reports 2008 Third Quarter Results
Nov 6, 2008
|
54.8 KB
|
| |
Iselin, NJ, November 6, 2008 - Pharmos Corporation (Nasdaq: PARS) today reported results for the third quarter ended September 30, 2008. The Company recorded a net loss of $2.8 million, or $0.11 per share, for the third quarter 2008 compared to a net loss of $3.5 million, or $0.14 per share, in the third quarter 2007. Cash and cash equiva...
|
|
 |
Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
Sep 26, 2008
|
8.8 KB
|
| |
Iselin, NJ, September 26, 2008 - Pharmos Corporation (Nasdaq: PARS) today announced that it received a Nasdaq Staff Determination on September 23, 2008 indicating that Pharmos fails to comply with the minimum bid price requirement for continued listing set forth in Marketplace Rule 4310©(4), and that the ...
|
|
 |
Pharmos Corporation Announces That it Will Cease Operations in Israel
Aug 29, 2008
|
9.5 KB
|
| |
ISELIN, N.J., Aug 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) today announced that effective October 31, 2008 it will cease operations in Rehovot, Israel, and manage those activities currently based in Rehovot out of the Company's US headquarters in Iselin, New Jersey.
The research programs in I...
|
|
 |
Pharmos Corporation Reports 2008 Second Quarter Results
Aug 7, 2008
|
13.2 KB
|
| |
ISELIN, N.J., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the second quarter ended June 30, 2008. The Company recorded a net loss of $2.7 million, or $0.10 per share, for the second quarter 2008 compared to a net loss of $4.6 million, or $0.18 per share, in the second ...
|
|
 |
Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
May 14, 2008
|
9.5 KB
|
| |
Iselin, N.J., May 14, 2008 — Pharmos Corporation (Nasdaq: PARS) announced today that its President and Chief Financial Officer, S. Colin Neill, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 5:15 PM Central Europe Daylight Time (GMT +2:00, or 11:15 AM Eastern Day...
|
|
 |
Pharmos Corporation Reports 2008 First Quarter Results
May 8, 2008
|
13.0 KB
|
| |
ISELIN, N.J., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the first quarter ended March 31, 2008. The Company recorded a net loss of $3.6 million, or $0.14 per share, for the first quarter 2008 compared to a net loss of $4.8 million, or $0.19 per share, in the first qua...
|
|
 |
Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
Feb 28, 2008
|
57.4 KB
|
| |
Iselin, NJ, February 28, 2008 - Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve-month period and ended December 31, 2007.
Fourth Quarter Ended December 31, 2007
For the fourth quarter ended December 31, 2007, Pharmos reported a net loss of $2.7 million, or $0.11 per...
|
|
 |
Pharmos Corporation Announces Board and Management Changes
Robert F. Johnston Named Executive Chairman of the Board; S. Colin Neill Named President
Jan 3, 2008
|
11.1 KB
|
| |
Iselin, NJ, January 3, 2008 - Pharmos Corporation (Nasdaq: PARS) announced today certain changes in its Board of Directors and Management, effective immediately.
Board Changes
Robert F. Johnston has been elected to the Board as Executive Chairman.
Haim Aviv, Ph.D., David Schlachet and Mo...
|
|
 |
Pharmos Corporation Completes Initial Closing of Private Placement
Jan 3, 2008
|
8.6 KB
|
| |
Iselin, NJ, January 3, 2008 - Pharmos Corporation (Nasdaq: PARS) announced today that it has completed an initial closing of a private placement of its 10% Convertible Debentures due November 2012. At the initial closing the Company issued $4,000,000 principal amount of the Debentures, at par, and received gross proceeds in the ...
|
|
 |
Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
Dec 18, 2007
|
9.7 KB
|
| |
ISELIN, N.J., Dec 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today that President & COO Alan Rubino has elected to resign from the Company.
Mr. Rubino joined Pharmos in November 2005 and was instrumental in the strategic acquisition and the subsequent integration of Vela Pharmaceutica...
|
|
 |
Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
Dec 10, 2007
|
10.0 KB
|
| |
ISELIN, N.J., Dec 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today that Chief Executive Officer Elkan R. Gamzu, Ph.D. will participate in a gastroenterology-focused panel discussion at the 2007 RBC Capital Markets Healthcare Conference taking place December 12 - 13, 2007 at the Westin New...
|
|
 |
Pharmos Corporation to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Nov 1, 2007
|
10.0 KB
|
| |
ISELIN, N.J., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today that its Chief Executive Officer, Elkan Gamzu, Ph.D., will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Monday, November 5, 2007 at 10:55 AM Eastern Time. The conference is taking place...
|
|
 |
Pharmos Corporation Reports 2007 Third Quarter Results
Oct 30, 2007
|
13.8 KB
|
| |
ISELIN, N.J., Oct 30, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the third quarter ended September 30, 2007. Net loss decreased 17% to $3.5 million, or $0.14 per share, for the third quarter 2007, from a net loss of $4.2 million, or $0.22 per share, in the third quarter 2006....
|
|
 |
Pharmos Restructures Operations in Israel
Oct 30, 2007
|
10.0 KB
|
| |
ISELIN, N.J., Oct 30, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today it is undertaking a second phase of restructuring as it continues to optimize the balance between cash resources and its most promising scientific research and development programs. This second phase involves a workforce r...
|
|
 |
Pharmos Receives Notice Related to Nasdaq Minimum Bid Price Rule
Sep 28, 2007
|
10.6 KB
|
| |
ISELIN, N.J., Sep 28, 2007 (PrimeNewswire via COMTEX News Network) -- Pharmos Corporation (Nasdaq:PARS) today announced that it received notice on September 26, 2007 from The Nasdaq Stock Market that the minimum bid price of its common stock had fallen below $1.00 for 30 consecutive business days and that Pharmos was therefore not in compliance wit...
|
|
 |
Pharmos Issues Letter to Shareholders
Sep 10, 2007
|
15.6 KB
|
| |
ISELIN, N.J., Sept 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) announced today it has issued the below Letter to Shareholders as part of its proxy materials for its annual meeting scheduled for October 24, 2007. Pharmos is among the first corporate issuers able to take advantage of the recently enac...
|
|
 |
Pharmos Corporation Reports 2007 Second Quarter Results
Aug 8, 2007
|
14.1 KB
|
| |
ISELIN, N.J., Aug 08, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the second quarter ended June 30, 2007. The Company recorded a net loss of $4.6 million, or $0.18 per share, for the second quarter 2007 compared to a net loss of $4.1 million, or $0.21 per share, in the second ...
|
|
|
= Add Release to Briefcase
|
 |
Stock Information
PARS - (NASD)
$0.13
- 0.00
|
Nov 20, 2008
4:00 PM ET |
|